Literature DB >> 3113780

The effect of transdermal oestrogen on bone, calcium-regulating hormones and liver in postmenopausal women.

P L Selby, M Peacock.   

Abstract

Transdermal oestradiol, 100 micrograms/d, was used to treat 11 women suffering from postmenopausal symptoms. After 3 weeks therapy there was a significant rise in the plasma oestradiol into the premenopausal range and a significant fall in plasma FSH level and symptom score. Bone resorption, assessed by urinary excretion of calcium and hydroxyproline, decreased significantly while plasma alkaline phosphatase activity remained constant. There was a significant fall in plasma calcium and phosphate but the plasma concentrations of PTH, calcitonin and calcitriol and the urinary excretion of cAMP were unchanged. Plasma levels of vitamin D binding protein, albumin and globulin were unaltered, and blood pressure did not rise. These effects were similar to those found in postmenopausal women with oral ethinyloestradiol, 30 micrograms/d, (Selby et al., 1985), apart from those on plasma vitamin D binding protein, total calcitriol, albumin, globulin, tubular reabsorption of phosphate and blood pressure, changes which probably arise from a direct action of oral oestrogen on the liver.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3113780     DOI: 10.1111/j.1365-2265.1986.tb03607.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  11 in total

1.  Guidelines on the management of osteoporosis associated with chronic liver disease.

Authors:  Jane D Collier; M Ninkovic; J E Compston
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

2.  Dose dependent response of symptoms, pituitary, and bone to transdermal oestrogen in postmenopausal women.

Authors:  M Peacock; P Selby
Journal:  Br Med J (Clin Res Ed)       Date:  1987-02-14

3.  Hepatic osteodystrophy: An important matter for consideration in chronic liver disease.

Authors:  Germán López-Larramona; Alfredo J Lucendo; Sonia González-Castillo; José M Tenias
Journal:  World J Hepatol       Date:  2011-12-27

4.  Adequacy of hormone replacement therapy for osteoporosis prevention assessed by serum oestradiol measurement, and the degree of association with menopausal symptoms.

Authors:  M Rodgers; J E Miller
Journal:  Br J Gen Pract       Date:  1997-03       Impact factor: 5.386

Review 5.  Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints.

Authors:  J A Balfour; R C Heel
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

6.  The application of plasma tartrate-resistant acid phosphatase to assess changes in bone resorption in response to artificial menopause and its treatment with estrogen or norethisterone.

Authors:  J J Stĕpán; J Pospíchal; V Schreiber; J Kanka; J Mensík; J Presl; V Pacovský
Journal:  Calcif Tissue Int       Date:  1989-11       Impact factor: 4.333

7.  Effect of salcatonin given intranasally on early postmenopausal bone loss.

Authors:  K Overgaard; B J Riis; C Christiansen; M A Hansen
Journal:  BMJ       Date:  1989-08-19

8.  The thyroid C cells of ovariectomized rats treated with estradiol.

Authors:  B Filipović; B Sosić-Jurjević; N Nestorović; M Manojlović Stojanoski; N Kostić; V Milosević; M Sekulić
Journal:  Histochem Cell Biol       Date:  2003-10-17       Impact factor: 4.304

9.  The heterogeneity of bone disease in cirrhosis: a multivariate analysis.

Authors:  Bronwyn A L Crawford; C Kam; A J Donaghy; G W McCaughan
Journal:  Osteoporos Int       Date:  2003-09-19       Impact factor: 4.507

10.  Hormone replacement therapy increases serum 1,25-dihydroxyvitamin D: A 2-year prospective study.

Authors:  H J van Hoof; M J van der Mooren; L M Swinkels; R Rolland; T J Benraad
Journal:  Calcif Tissue Int       Date:  1994-12       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.